By Charlie G ❘ 2008

Today I read an interesting story:

An experimental drug for diabetes dispenses insulin in response to glucose levels.

SmartCells biotechnology company in the U.S. is developing a drug that could do most of the work in the control of diabetes.

The injectable drug, called SmartInsulin, detects elevated glucose levels and automatically dispenses insulin as needed. As glucose levels fall, the medicine is stabilized, retaining the insulin until the next sugar rush.

A drug like this could reduce the number of required insulin injections per day.

Todd Zion, SmartCells founder and president, says that a drug that is self-regulated like this can also reduce the risk of hypoglycemia, a potential danger associated with current therapies for diabetes.

The company has tested the drug on hundreds of rodents and has recently been experimenting with pigs that do not produce enough insulin – models that are more similar to human diabetes.

So far, Zion’s team found that the drug is able to detect and adapt to fluctuating glucose levels and provide insulin as needed, maintaining stable levels while avoiding an overdose of insulin that could lead to hypoglycemia.

Zion intends to begin clinical trials within the next two years. Last week, SmartCells received $1,000,000 to fund studies on the safety and efficacy of the drug in preclinical trials with animals, as part of a collaboration with the Juvenile Diabetes Research Foundation.

You can read the full story here: Smart Insulin

 

Was this article helpful? Please, rate accordingly
(1 star=Not at all, 3 stars=Somehow, 5 stars=Yes, a lot!)
1 Star2 Stars3 Stars4 Stars5 Stars (1 votes, average: 5.00 out of 5)

Tags: ,